|
Craneware PLC on Friday said its ‘positive momentum’ has continued at the start of the 2026 financial year. The Edinburgh, Scotland-based software solutions provider said its alliance with Microsoft Corp is ‘progressing well’, and it has added ‘significant sales pipeline growth’. In a statement ahead of Friday’s annual general meeting, the company said it has continued to invest in research and development to use its proprietary data to launch new artificial intelligence-enabled applications. Craneware said it has recently been focused on the development of a product to support customers through the 340B drug rebate pilot programme, where participating hospitals have to purchase nine named drugs at wholesale acquisition cost and later apply for manufacturer rebates. ‘As a result of prior investments in the Trisus platform, the depth of Craneware’s data and its unique position of independence in the 340B vendor market, the company has successfully brought this fully integrated solution to market in an accelerated timeframe, supporting its customers by reducing their financial risk, maintaining compliance and protecting resources for patient care,’ the firm said. It added that the solution is now being rolled out ahead of the deadline. Craneware said it remains confident of continued growth in the near term and noted that it continues to trade in line with market expectations for the year. ‘The strength of the company’s Annuity [software-as-a-service] business model and balance sheet, its high levels of recurring revenue and strong cash generation provide Craneware with solid foundations as it executes on its growth strategy and the creation of long-term value for all stakeholders,’ it said. Shares in Craneware were up 1.5% at 2,151.00 pence on Friday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
